Podcasts about myelofibrosis

  • 100PODCASTS
  • 361EPISODES
  • 43mAVG DURATION
  • 5WEEKLY NEW EPISODES
  • Jun 13, 2025LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about myelofibrosis

Show all podcasts related to myelofibrosis

Latest podcast episodes about myelofibrosis

The Bloodline with LLS
Choosing the Path Forward: Shared Decisions in Myelofibrosis Care

The Bloodline with LLS

Play Episode Listen Later Jun 13, 2025 31:12


In this episode, we speak with Mary Wells, who was diagnosed with primary myelofibrosis in 2018, a rare blood cancer… The post Choosing the Path Forward: Shared Decisions in Myelofibrosis Care first appeared on The Bloodline with LLS.

Research To Practice | Oncology Videos
Myelofibrosis — Year in Review Series on Relevant New Datasets and Advances

Research To Practice | Oncology Videos

Play Episode Listen Later Jun 13, 2025 59:19


Featuring perspectives from Prof Claire Harrison and Dr John Mascarenhas, including the following topics: Introduction (0:00) New Biology of Myelofibrosis (1:55) Novel Regulatory T-Cell Infusion Therapy (14:57) Myelofibrosis 2025: JAK Inhibitors (Ruxolitinib) (20:39) BET Inhibitors: Pelabresib (42:03) Navtemadlin (53:20) CME information and select publications

Research To Practice | Oncology Videos
Myelofibrosis | Professor Claire Harrison

Research To Practice | Oncology Videos

Play Episode Listen Later Jun 12, 2025 46:48


Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Myelofibrosis | Faculty Presentation 1: Current Management of Myelofibrosis (MF) — Professor Claire Harrison CME information and select publications

Research To Practice | Oncology Videos
Myelofibrosis | John Mascarenhas, MD

Research To Practice | Oncology Videos

Play Episode Listen Later Jun 12, 2025 32:33


Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Myelofibrosis | Faculty Presentation 2: Novel Investigational Strategies — John Mascarenhas, MD CME information and select publications

Hematologic Oncology Update
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Myelofibrosis

Hematologic Oncology Update

Play Episode Listen Later Jun 11, 2025 59:18


Professor Claire Harrison from the Guy's and St Thomas' NHS Foundation Trust in London, United Kingdom, and Dr John Mascarenas from The Tisch Cancer Institute in New York, New York, provide their perspectives on relevant new clinical data in myelofibrosis and discuss their application to treatment. CME information and select publications here.

Research To Practice | Oncology Videos
Systemic Mastocytosis and Myelofibrosis — Fourth Annual National General Medical Oncology Summit

Research To Practice | Oncology Videos

Play Episode Listen Later Jun 2, 2025 47:56


Featuring perspectives from Dr Prithviraj Bose and Dr Andrew T Kuykendall, including the following topics: Systemic Mastocytosis — Dr Bose (0:00) Myelofibrosis — Dr Kuykendall (24:46) CME information and select publications

Hematologic Oncology Update
Systemic Mastocytosis and Myelofibrosis — Fourth Annual National General Medical Oncology Summit

Hematologic Oncology Update

Play Episode Listen Later Jun 2, 2025 47:55


Clinical investigators discuss available data guiding the management of systemic mastocytosis and myelofibrosis.  CME information and select publications here.

PVRoundup Podcast
Revisiting Anemia Response in Myelofibrosis: Revised International Working Group Criteria

PVRoundup Podcast

Play Episode Listen Later May 20, 2025 7:21


Drs. Pemmaraju and Bose discuss the revised International Working Group criteria for anemia response in patients with myelofibrosis, outlining new definitions for transfusion status, gender-specific hemoglobin thresholds, and benchmarks for major and minor responses.

PVRoundup Podcast
Leukemic Transformation in Myelofibrosis: Risks, Realities, and Evolving Strategies

PVRoundup Podcast

Play Episode Listen Later May 19, 2025 7:34


Drs. Bose and Pemmaraju discuss leukemic transformation in patients with myelofibrosis, reviewing its incidence, as well as risk factors, treatment, and prognosis.

PVRoundup Podcast
Understanding Secondary Myelofibrosis: Diagnosis, Treatment, and Prognosis

PVRoundup Podcast

Play Episode Listen Later May 16, 2025 6:08


Drs. Bose and Pemmaraju review secondary myelofibrosis arising from polycythemia vera or essential thrombocythemia and how it differs from primary myelofibrosis that develops de novo.

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Sara M. Tinsley-Vance, PhD, APRN, AOCN - Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later May 12, 2025 88:12


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Sara M. Tinsley-Vance, PhD, APRN, AOCN - Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 12, 2025 88:12


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Sara M. Tinsley-Vance, PhD, APRN, AOCN - Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later May 12, 2025 88:12


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Sara M. Tinsley-Vance, PhD, APRN, AOCN - Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later May 12, 2025 88:12


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Sara M. Tinsley-Vance, PhD, APRN, AOCN - Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 12, 2025 88:12


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Sara M. Tinsley-Vance, PhD, APRN, AOCN - Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 12, 2025 88:12


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Sara M. Tinsley-Vance, PhD, APRN, AOCN - Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 12, 2025 88:12


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Sara M. Tinsley-Vance, PhD, APRN, AOCN - Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later May 12, 2025 88:12


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

Research To Practice | Oncology Videos
Myelofibrosis — An Interview with Dr Raajit K Rampal on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting (Companion Faculty Lecture)

Research To Practice | Oncology Videos

Play Episode Listen Later Apr 16, 2025 31:10


Featuring a slide presentation and related discussion from Dr Raajit K Rampal, including the following topics: Overview of the current JAK inhibitor landscape (0:00) Factors predicting clinical benefit in patients with myelofibrosis (MF) receiving ruxolitinib (3:02) Clinical data supporting the use of fedratinib after prior ruxolitinib for MF (9:17) Emerging clinical findings on pelabresib in combination with ruxolitinib for previously untreated MF (12:13) Available clinical data with novel BET inhibitors (15:00) Utility of selinexor in combination with ruxolitinib for MF previously treated with ruxolitinib (16:50) Emerging efficacy and safety findings reported with imetelstat for MF (18:57) Clinical findings reported with the MDM2 inhibitor navtemadlin for MF (21:15) Available clinical data with the TGF-beta inhibitor elritercept for MF (24:05) Other novel agents and strategies under investigation for MF (26:06) CME information and select publications

Research To Practice | Oncology Videos
Myelofibrosis — An Interview with Dr Raajit K Rampal on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting

Research To Practice | Oncology Videos

Play Episode Listen Later Apr 16, 2025 43:18


Featuring an interview with Dr Raajit K Rampal, including the following topics: Clinical decision-making in the initiation and stopping of systemic therapy for myelofibrosis (MF) (0:00) Novel research strategies involving CDK4/6 inhibitors for MF (8:03) Implications of the JUMP study for clinical practice (10:00) Therapeutic switching strategies with JAK inhibitors for MF (12:17) Clinical rationale for the use of luspatercept and elritercept for MF (15:35) Emerging clinical data involving BET inhibitors for MF (16:57) Tolerability concerns with selinexor in patients with MF (20:01) Mechanism of and clinical data with the MDM2 inhibitor navtemadlin for MF (22:32) Additional novel strategies under clinical investigation for MF (25:52) Potential transformation of myeloproliferative neoplasms to acute myeloid leukemia (29:40) Management of polycythemia vera and essential thrombocythemia (34:27) General management principles for myeloproliferative neoplasms (37:53) CME information and select publications

Hematologic Oncology Update
Myelofibrosis — An Interview with Dr Raajit K Rampal on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting

Hematologic Oncology Update

Play Episode Listen Later Apr 15, 2025 43:18


Dr Raajit K Rampal from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent updates on available and novel treatment strategies for myelofibrosis. CME information and select publications here.

PVRoundup Podcast
Could a new combination improve first-line therapy for myelofibrosis?

PVRoundup Podcast

Play Episode Listen Later Mar 26, 2025 4:57


A phase 3 study showed that combining pelabresib with ruxolitinib significantly improved spleen volume reduction and symptom relief in myelofibrosis patients compared to ruxolitinib alone, offering a promising new treatment option. Long-term use of gantenerumab may delay Alzheimer's dementia onset in individuals with inherited Alzheimer's, supporting the amyloid hypothesis and paving the way for future prevention strategies. Phase 3 trials demonstrated that povorcitinib, an oral JAK1 inhibitor, significantly improved clinical outcomes in adults with moderate to severe hidradenitis suppurativa, potentially offering a new treatment option. Research linked red meat allergy to bites from additional tick species, expanding the geographic risk area and highlighting the need for clinicians to consider this diagnosis in patients with unexplained allergic symptoms following tick bites.

PeerVoice Oncology & Haematology Audio
Alessandro M. Vannucchi, MD, PhD - Not All JAKis Are Equal: What Can Trials and Real-World Evidence Tell Us About Optimal Treatment Approaches in Myelofibrosis?

PeerVoice Oncology & Haematology Audio

Play Episode Listen Later Mar 26, 2025 18:36


Alessandro M. Vannucchi, MD, PhD - Not All JAKis Are Equal: What Can Trials and Real-World Evidence Tell Us About Optimal Treatment Approaches in Myelofibrosis?

PeerVoice Oncology & Haematology Video
Alessandro M. Vannucchi, MD, PhD - Not All JAKis Are Equal: What Can Trials and Real-World Evidence Tell Us About Optimal Treatment Approaches in Myelofibrosis?

PeerVoice Oncology & Haematology Video

Play Episode Listen Later Mar 26, 2025 18:36


Alessandro M. Vannucchi, MD, PhD - Not All JAKis Are Equal: What Can Trials and Real-World Evidence Tell Us About Optimal Treatment Approaches in Myelofibrosis?

PeerVoice Internal Medicine Audio
Alessandro M. Vannucchi, MD, PhD - Not All JAKis Are Equal: What Can Trials and Real-World Evidence Tell Us About Optimal Treatment Approaches in Myelofibrosis?

PeerVoice Internal Medicine Audio

Play Episode Listen Later Mar 26, 2025 18:36


Alessandro M. Vannucchi, MD, PhD - Not All JAKis Are Equal: What Can Trials and Real-World Evidence Tell Us About Optimal Treatment Approaches in Myelofibrosis?

PeerVoice Internal Medicine Video
Alessandro M. Vannucchi, MD, PhD - Not All JAKis Are Equal: What Can Trials and Real-World Evidence Tell Us About Optimal Treatment Approaches in Myelofibrosis?

PeerVoice Internal Medicine Video

Play Episode Listen Later Mar 26, 2025 18:36


Alessandro M. Vannucchi, MD, PhD - Not All JAKis Are Equal: What Can Trials and Real-World Evidence Tell Us About Optimal Treatment Approaches in Myelofibrosis?

PeerVoice Oncology & Haematology Video
Claire Harrison, DM, FRCP, FRCPath - Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations on Treatment Goals and Decisions

PeerVoice Oncology & Haematology Video

Play Episode Listen Later Mar 5, 2025 20:00


Claire Harrison, DM, FRCP, FRCPath - Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations on Treatment Goals and Decisions

PeerVoice Oncology & Haematology Audio
Claire Harrison, DM, FRCP, FRCPath - Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations on Treatment Goals and Decisions

PeerVoice Oncology & Haematology Audio

Play Episode Listen Later Mar 5, 2025 20:00


Claire Harrison, DM, FRCP, FRCPath - Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations on Treatment Goals and Decisions

PeerVoice Internal Medicine Audio
Claire Harrison, DM, FRCP, FRCPath - Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations on Treatment Goals and Decisions

PeerVoice Internal Medicine Audio

Play Episode Listen Later Mar 5, 2025 20:00


Claire Harrison, DM, FRCP, FRCPath - Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations on Treatment Goals and Decisions

Research To Practice | Oncology Videos
Myelofibrosis | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Myelofibrosis

Research To Practice | Oncology Videos

Play Episode Listen Later Jan 14, 2025 119:15


Featuring perspectives from Dr Alexander Perl, Dr Eytan M Stein, Dr Richard M Stone, Dr Eunice S Wang and Prof Andrew H Wei, moderated by Dr Stein, including the following topics: Introduction (0:00) Current Clinical Decision-Making for Myelofibrosis (MF) in the Absence of Severe Cytopenias — Dr Kuykendall (2:53) Managing MF for Patients with Thrombocytopenia — Dr Bose (32:45) Managing MF for Patients with Anemia — Dr Yacoub (59:47) Future Directions in the Management of MF — Dr Fleischman (1:27:53) CME information and select publications

Hematologic Oncology Update
Myelofibrosis — Part 4 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

Hematologic Oncology Update

Play Episode Listen Later Jan 14, 2025 119:14


Dr Prithviraj Bose from The University of Texas MD Anderson Cancer Center in Houston, Dr Angela G Fleischman from UC Irvine Health in Irvine, California, Dr Abdulraheem Yacoub from The University of Kansas Cancer Center in Westwood and Dr Andrew T Kuykendall from Moffitt Cancer Center in Tampa, Florida, discuss recent updates on available and novel treatment strategies for myelofibrosis.

Oncology Today with Dr Neil Love
Myelofibrosis — Part 4 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

Oncology Today with Dr Neil Love

Play Episode Listen Later Jan 13, 2025 119:14


Dr Prithviraj Bose from The University of Texas MD Anderson Cancer Center in Houston, Dr Angela G Fleischman from UC Irvine Health in Irvine, California, Dr Abdulraheem Yacoub from The University of Kansas Cancer Center in Westwood and Dr Andrew T Kuykendall from Moffitt Cancer Center in Tampa, Florida, discuss recent updates on available and novel treatment strategies for myelofibrosis, moderated by Dr Kuykendall. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/ASHMF24).

PVRoundup Podcast
Clinical Trials in Myelofibrosis: Endpoints

PVRoundup Podcast

Play Episode Listen Later Jan 9, 2025 13:49


Drs. Komrokji and Kuykendall review the evolution of clinical trial endpoints in myelofibrosis studies. They discuss traditional measures of disease control, such as spleen volume reduction and hematologic response, as well as expanded endpoints that reflect the biological and symptomatic aspects of myelofibrosis.

PVRoundup Podcast
Cytopenic Myelofibrosis

PVRoundup Podcast

Play Episode Listen Later Jan 8, 2025 11:06


Andrew Kuykendall, MD and Rami Komrokji, MD discuss cytopenic myelofibrosis, reviewing how these patients typically present. They also cover mutational burden, specific treatment strategies, and prognosis in patients with the cytopenic phenotype.

PVRoundup Podcast
American Society of Hematology Annual Meeting 2024 – Updates in Myelofibrosis (Part 2)

PVRoundup Podcast

Play Episode Listen Later Jan 7, 2025 8:51


Dr. Angela Fleischman and Dr. Gabriella Hobbs discussed two intriguing abstracts presented at the ASH 2024 Annual Meeting about emerging treatments for myelofibrosis. The first study, led by Dr. Lucia Massarova, explored the safety and preliminary efficacy of cord blood-derived CXCR4-enriched T-regulatory cells in patients with suboptimal response to ruxolitinib, showing minimal adverse events and potential improvements in hemoglobin, spleen size, and symptoms. The second study evaluated nuvusertib (TP3654), a selective PIM1 kinase inhibitor, in patients with relapsed/refractory myelofibrosis, demonstrating stable hemoglobin and platelet levels, symptom and spleen volume improvement, and preliminary evidence of fibrosis and cytokine response.

PVRoundup Podcast
American Society of Hematology Annual Meeting 2024 – Updates in Myelofibrosis (Part 1)

PVRoundup Podcast

Play Episode Listen Later Jan 6, 2025 8:12


In this episode of the Peer Direct Specialist Spotlight, Gabriella Hobbs, MD and Angela Fleischman, MD, PhD discuss updates from the ASH 2024 annual meeting on emerging therapies for myelofibrosis, focusing on two agents: ilritracept and PXS-5505. Ilritracept, a modified ligand trap, showed promise in improving anemia, transfusion burden, spleen size, and symptoms, with data suggesting potential benefits in addressing ruxolitinib-associated cytopenias. PXS-5505, a pan-LOX inhibitor with antifibrotic effects, was evaluated in combination with ruxolitinib, highlighting the role of antifibrotic agents as adjunctive therapies.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Professor Claire Harrison, DM - Mastering the Art of Myelofibrosis Care: Expert Guidance, Clinical Experience, and Innovation for More Personalized Disease Control

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 6, 2025 7:17


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EMK865. CME/MOC/AAPA credit will be available until January 5, 2026.Mastering the Art of Myelofibrosis Care: Expert Guidance, Clinical Experience, & Innovation for More Personalized Disease Control In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Bristol Myers Squibb, Geron, GSK, and CTI BioPharma Corp., a Sobi Company.Disclosure information is available at the beginning of the video presentation.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Professor Claire Harrison, DM - Mastering the Art of Myelofibrosis Care: Expert Guidance, Clinical Experience, and Innovation for More Personalized Disease Control

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 6, 2025 94:23


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EMK865. CME/MOC/AAPA credit will be available until January 5, 2026.Mastering the Art of Myelofibrosis Care: Expert Guidance, Clinical Experience, & Innovation for More Personalized Disease Control In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Bristol Myers Squibb, Geron, GSK, and CTI BioPharma Corp., a Sobi Company.Disclosure information is available at the beginning of the video presentation.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Professor Claire Harrison, DM - Mastering the Art of Myelofibrosis Care: Expert Guidance, Clinical Experience, and Innovation for More Personalized Disease Control

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 6, 2025 94:23


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EMK865. CME/MOC/AAPA credit will be available until January 5, 2026.Mastering the Art of Myelofibrosis Care: Expert Guidance, Clinical Experience, & Innovation for More Personalized Disease Control In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Bristol Myers Squibb, Geron, GSK, and CTI BioPharma Corp., a Sobi Company.Disclosure information is available at the beginning of the video presentation.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Professor Claire Harrison, DM - Mastering the Art of Myelofibrosis Care: Expert Guidance, Clinical Experience, and Innovation for More Personalized Disease Control

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 6, 2025 7:17


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EMK865. CME/MOC/AAPA credit will be available until January 5, 2026.Mastering the Art of Myelofibrosis Care: Expert Guidance, Clinical Experience, & Innovation for More Personalized Disease Control In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Bristol Myers Squibb, Geron, GSK, and CTI BioPharma Corp., a Sobi Company.Disclosure information is available at the beginning of the video presentation.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Professor Claire Harrison, DM - Mastering the Art of Myelofibrosis Care: Expert Guidance, Clinical Experience, and Innovation for More Personalized Disease Control

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 6, 2025 7:17


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EMK865. CME/MOC/AAPA credit will be available until January 5, 2026.Mastering the Art of Myelofibrosis Care: Expert Guidance, Clinical Experience, & Innovation for More Personalized Disease Control In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Bristol Myers Squibb, Geron, GSK, and CTI BioPharma Corp., a Sobi Company.Disclosure information is available at the beginning of the video presentation.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Professor Claire Harrison, DM - Mastering the Art of Myelofibrosis Care: Expert Guidance, Clinical Experience, and Innovation for More Personalized Disease Control

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Jan 6, 2025 94:23


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EMK865. CME/MOC/AAPA credit will be available until January 5, 2026.Mastering the Art of Myelofibrosis Care: Expert Guidance, Clinical Experience, & Innovation for More Personalized Disease Control In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Bristol Myers Squibb, Geron, GSK, and CTI BioPharma Corp., a Sobi Company.Disclosure information is available at the beginning of the video presentation.

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
Professor Claire Harrison, DM - Mastering the Art of Myelofibrosis Care: Expert Guidance, Clinical Experience, and Innovation for More Personalized Disease Control

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 6, 2025 7:17


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EMK865. CME/MOC/AAPA credit will be available until January 5, 2026.Mastering the Art of Myelofibrosis Care: Expert Guidance, Clinical Experience, & Innovation for More Personalized Disease Control In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Bristol Myers Squibb, Geron, GSK, and CTI BioPharma Corp., a Sobi Company.Disclosure information is available at the beginning of the video presentation.

Research To Practice | Oncology Videos
Myelofibrosis | Cases from the Community: Integrating New Research Findings into Practice

Research To Practice | Oncology Videos

Play Episode Listen Later Dec 17, 2024 51:44


Featuring perspectives from Dr Stephen T Oh, moderated by Dr Stephen “Fred” Divers CME information and select publications

Oncology Today with Dr Neil Love
Cases from the Community: Integrating New Research Findings into Current Practice — Myelofibrosis

Oncology Today with Dr Neil Love

Play Episode Listen Later Dec 17, 2024 51:43


Dr Stephen T Oh shares his perspectives on the evolving therapeutic landscape for patients with myelofibrosis, moderated by Dr Stephen "Fred" Divers. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/AON24).

Hematologic Oncology Update
Cases from the Community: Integrating New Research Findings into Current Practice — Myelofibrosis

Hematologic Oncology Update

Play Episode Listen Later Dec 17, 2024 51:43


Dr Stephen T Oh shares his perspectives on the evolving therapeutic landscape for patients with myelofibrosis.

PVRoundup Podcast
Managing the Signs and Symptoms of Myelofibrosis

PVRoundup Podcast

Play Episode Listen Later Nov 29, 2024 8:23


John Mascarenhas, MD and Kathryn Johnson, DNP, MSc, FNP‑BC discuss the common signs and symptoms seen in patients with myelofibrosis and share insights into how they go about addressing them. They review anemia and splenomegaly, platelet-related symptoms of bleeding and thrombosis, and constitutional symptoms.

PVRoundup Podcast
Clinical Trials in Myelofibrosis: Referral, Recruitment, and Assessment

PVRoundup Podcast

Play Episode Listen Later Nov 28, 2024 10:53


Dr. Mascarenhas and Kathryn Johnson review important considerations for referring physicians in clinical trials for myelofibrosis. They cover timing for referral, referral pathways, and appropriate patients, as well as assessments, monitoring, and even logistical considerations.

Blood Podcast
Bone marrow failure related to ERG insufficiency, factor 11 in vascular hyperpermeability, and new criteria for evaluating anemia in myelofibrosis

Blood Podcast

Play Episode Listen Later Oct 24, 2024 20:32


In this week's episode we'll learn more about the role of ERG loss-of-function variants in bone marrow failure and hematological malignancies, a proposed pathway linking factor 11 activation to increased vascular permeability during inflammation, and new clinical criteria for diagnosing anemia, defining transfusion-dependence, and evaluating anemia treatment responses in patients with myelofibrosis.Featured Articles:Germ line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predispositionCoagulation factor XI regulates endothelial cell permeability and barrier function in vitro and in vivoProposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

OncLive® On Air
S11 Ep23: Navigating Myelofibrosis: Updates for Community Hematologist Oncologists

OncLive® On Air

Play Episode Listen Later Oct 14, 2024 25:38


In today's episode, supported by Sobi, we had the pleasure of speaking with Aaron T. Gerds, MD, MS, and James K. McCloskey, MD, about myelofibrosis treatment advances. Dr Gerds is an assistant professor in the Department of Medicine in the School of Medicine, as well as a member of the Developmental Therapeutics Program at the Case Comprehensive Cancer Center in Cleveland, Ohio. He is also a physician in the Department of Hematology and Medical Oncology at Cleveland Clinic. Dr McCloskey is the interim chief of the Division of Leukemia at Hackensack John Theurer Cancer Center in New Jersey.  In our exclusive interview, Drs Gerds and McCloskey discussed factors that influence their choice between the variety of JAK inhibitors that are FDA approved for patients with myelofibrosis, tips for symptom management in this disease, and emerging myelofibrosis research to look out for.